LOS ANGELES, March 31, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) announces the release of its 2021 Annual Report on the OTC Markets. The Company ended the year with $514,007 in revenue, compared to only $11,468 the previous year. This is an increase of $502,539, or 4382%. Gross profits for the same period grew from just $10,831 in 2020 to $511,335 in 2021, representing an increase of 4621%. Total assets in 2021 more than doubled over the previous year, growing from $120,476 in 2021 to $275,021, for an increase of 123%. The Company also reduced its total liabilities more than 25% from $3,631,096 in 2020 to $2,710,201 in 2021.
President and CEO, Dr. Chris Otiko said, “Last year was a breakthrough year in many ways for ViaDerma. Despite the significant revenue growth we experienced, 2021 could have been better had it not been for some COVID-19 related setbacks that affected our distribution during the fourth quarter. Those issues have now been resolved and production of Vitastem has resumed. We are expecting delivery of the product to our inventory in the next few weeks and hope to resume online sales on Amazon and other platforms shortly.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: info@viadermalicensing.com
Phone: 310-734-6111
Follow us on Twitter: ViaDerma Official @viaderma
Like us on Facebook: ViaDerma-VDRM @viadermapharma
